TB-500 vs GHK-Cu: Special Populations Head-to-Head Comparison At a glance TB-500 source / active fragment of thymosin beta-4, a 43-amino-acid protein GHK-Cu source / tripeptide (Gly-His-Lys) complexed with copper(II) ion Primary TB-500 mechanism / actin sequestration, anti-inflammatory cytokine modulation, angiogenesis Primary GHK-Cu mechanism / TGF-beta and VEGF upregulation, collagen synthesis, antioxidant gene activation TB-500 typical dose / 2 to 5 mg subcutaneous injection 2x per week (loading), then 1 to 2 mg weekly GHK-Cu typical dose / 0.5 to 2 mg subcutaneous or topical (skin)
Plant Biotechnol Molec Markers, pp 195205
Potential Limitations and Cautions While AOD 9604s prospects seem promising, its pivotal to acknowledge potential limitations: Data on long-term safety is still in the nascent stages
No assurance can be given that future events will occur, that projections will be achieved, or that GLPs assumptions are correct.
Testing is the best way to confirm a deficiency before supplementing
This means your skin can actually start repairing itself at the foundational level